Is a Real Hair Loss Breakthrough Finally Coming?
#Hair Loss Breakthrough #AI-Designed Antibodies #Oral Minoxidil #Prolactin Receptors #Hair Restoration #Clinical Trials #Hair Growth
📌 Key Takeaways
- Extended-release oral minoxidil in phase three trials shows nearly three times better results than current options
- AI-designed antibody therapy targets prolactin receptors to shift hair follicles from resting to growth phase
- Human trials for the antibody treatment are currently underway in Australia after promising animal studies
- These treatments are complementary rather than competing approaches to hair restoration
📖 Full Retelling
Dr. David J. Goldberg, a prominent dermatologist from Schweiger Dermatology Group in New York, revealed significant advancements in hair loss treatments during a recent episode of The Beauty Authority on February 26, 2026, addressing the growing demand for effective solutions as hair thinning cases increase, particularly among women in their 40s and 50s, and shedding associated with popular weight loss medications. One promising development is an extended-release version of oral minoxidil currently in phase three clinical trials by Veradermics. Unlike the current formulation that was originally developed as a blood pressure medication and creates inconsistent drug levels in the bloodstream, this new version delivers a steady dose over time. Dr. Goldberg explains that the current minoxidil works by dilating blood vessels to create a healthy environment for hair growth, but its rapid peak and drop-off in concentration limit effectiveness. Phase two data indicates the extended-release version performed nearly three times better than currently available options, potentially reaching the market within the next few years if trials continue successfully. Another revolutionary approach is an AI-designed antibody therapy from AbSci that targets the prolactin receptor on hair follicles, a connection previously unrecognized by many dermatologists. This treatment, ABS-201, aims to address androgenetic alopecia by blocking the prolactin receptor, helping shift hair follicles from the resting phase into active growth. Early studies in rodents and macaque monkeys have shown significant regrowth, with phase one human trials currently underway in Australia. Unlike daily pills, this therapy would likely involve a series of injections over several months, potentially maintaining results for up to a year after treatment.
🏷️ Themes
Medical Innovation, Dermatology Advances, Biotechnology
📚 Related People & Topics
Clinical trial
Phase of clinical research in medicine
Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and ...
Management of hair loss
The management of hair loss, includes prevention and treatment of alopecia, baldness, and hair thinning, and regrowth of hair.
Entity Intersection Graph
Connections for Clinical trial:
🌐
MHRA
1 shared
🌐
Transgender youth
1 shared
🌐
Gender identity
1 shared
🌐
Puberty blocker
1 shared
🌐
Insider trading
1 shared
Original Source
Is a Real Hair Loss Breakthrough Finally Coming? Smarter oral therapies and AI-designed antibody injections are on the horizon. Tatiana Bido Published: Feb 26, 2026 Photo by Andres Perez on Unsplash Hair loss is no longer a niche concern. Dermatologists are seeing more patients than ever, especially women in their 40s and 50s, who are distressed about thinning. Add the rise of GLP-1 medications and the shedding that can accompany rapid weight loss, and the demand for better solutions is only growing. On a recent episode of The Beauty Authority , New York dermatologist David J. Goldberg, MD, of Schweiger Dermatology Group, shared why he believes we’re entering a new era in hair restoration —and what patients can realistically expect in the next few years. A New, Improved Hair Loss Pill Oral minoxidil has gained traction in recent years as an effective treatment option, but it was originally developed as a blood pressure medication, not a hair-growth drug. “The current formulation was not made for hair growth. It was made for blood pressure,” Dr. Goldberg explains. Because it peaks quickly in the bloodstream and then drops off, the hair follicle is not exposed to the medication long enough to maximize results. “Minoxidil works by really dilating blood vessels. It creates a healthy environment around the hair, which allows hair to grow,” he says. “If you get that drop, then we know it’s not going to work as well.” An extended-release version of oral minoxidil, now in phase three trials and developed by Veradermics, aims to solve that problem. Instead of spiking and fading, it delivers a steady dose over time. “We never get that high peak,” Dr. Goldberg says. “Think of it as creating healthy nutrition for the hair.” In phase two data, he notes, it performed nearly three times better than currently available options. The treatment is not yet FDA-approved, but if trials continue successfully, it could reach the market within the next few years. The AI Breakthrough Changin...
Read full article at source